Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was being sarcastic, trying to make an obviously poor joke.
I'm thinking more of what he was.
BMO 515
Citi 600
BoA 872
Is the BOA (Merrill) analyst named Henry Blodget by any chance?
lax, that post is much too reasonable for your interlocutor to digest.
The SHO,Naked Shorting and a HB /SEC announcement Of a criminal Investigation will create a ShortbSQUEEZE !
You're right, it might. But there won't be a criminal investigation initiated by the SEC. If you have information to the contrary, post it.
Wonder if you'll get a reply.
HES is the largest single franchisee of Dunkin’ Donuts
Oh dear. That means I'll have to sell my HES on ethical grounds.
Meaning the transaction took place at the ask? If so, I'll concede you that one.
They are working hard to accumulate.
Or divest.
You are right. And it's still a quarterback option strategy, it would seem
< Back
Hess Files Form 10 Registration Statement Related to Spin Off of Retail Business
NEW YORK--(BUSINESS WIRE)--Jan. 8, 2014-- Hess Corporation announced today that Hess Retail Corporation, its wholly owned subsidiary, has filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC).
The Form 10 contains a preliminary information statement about the potential terms and conditions of a spin-off of Hess Retail Corporation to the stockholders of Hess Corporation. It also includes information about Hess Retail Corporation as a standalone company, including financial, capital structure, business, risk factor and management and governance information. The preliminary information statement is subject to change. The Form 10 is available on the SEC's website at http://www.sec.gov and on Hess’ website at www.hess.com.
Hess Corporation also announced that it has received a Private Letter Ruling from the Internal Revenue Service that will allow Hess Corporation to distribute the business to stockholders in a tax-free spin-off.
Simultaneous with pursuing a spin of the retail business, Hess Corporation will also solicit offers to purchase the entire retail business from potential buyers. Following receipt of any such offers, the Hess Corporation Board of Directors will determine which alternative it believes best serves the long term interests of all Hess Corporation stockholders.
MOS/POT/AGU coming out of doldrums, perhaps.
(EDIT - there may be others of that ilk, but those are the ones I have on a screen.)
It has filed a registration statement which may suggest its current thinking.
FT
US energy company Hess spent the first half of last year fighting a battle with activist investor Elliott Management. Almost a year later, the company has announced plans to spin off its gas station and retail business.
Under the plan, Hess shareholders will receive shares in a new Hess Retail company, which will own and run the more than 1,300 petrol stations and convenience stores that Hess has in the US.
In a filing with the Securities and Exchange Commission, Hess said:
The board of directors of Hess believes the separation and the distribution will enable each company to:
pursue a more focused, industry-specific strategy
allocate resources and deploy capital in a manner consistent with its own priorities
Under pressure from Elliott, Hess last year committed to disposing of oil and gas fields in Indonesia and Thailand
GS increased their ARIA p/T to $6
What's the current price?
Especially as these crops are round up resistant.
(Would that make difference?)
ilpapa--I take it you are volunteering to put a little round up on your food each meal?
Did I even come close to saying ANYTHING of the kind?
By its super green standards, the NYT piece does a very good job of debunking the anti science stand of those favoring a total ban.
And that is the significance of the anti GMO movement - the harm it can do to efforts to grow food production. Whether that benefits Monsanto or not.
Colorado School of mines graduates earn starting salaries higher than Harvard Business School grads.
http://abcnews.go.com/Business/12-colleges-job-payoff-harvard/story?id=17273504
Ask and you shall receive.
Business
Merck Plans Radical Overhaul of Drug R&D Unit
By
Peter Loftus And
Jonathan D. Rockoff
Updated Dec. 27, 2013 4:50 p.m. ET
Merck & Co. is working on a plan to radically reshape its once-storied research-and-development unit that would create international innovation hubs tapping into drug research outside of its labs.
Merck would create these hubs in or near Boston, the San Francisco Bay area, London and Shanghai, according to people familiar with the matter—regions with a critical mass of academic and commercial R&D. The company would use the bases to scout for promising biotechnology and pharmaceutical research that Merck could license or acquire in deals, according to these people.
Meantime, the company is pruning its own research pipeline. Merck has identified dozens of compounds under study at its labs that it wants to sell off, according to a person familiar with the matter and an internal planning document reviewed by The Wall Street Journal. Among them are experimental glaucoma treatments, some antipsychotics and a male fertility drug, according to the document.
R&D setbacks have made it harder for Merck to weather patent expirations for top-selling drugs such as the allergy and asthma medication Singulair. Now, they have prompted the company to rethink its inward-looking approach to drug R&D. Associated Press
A Merck spokesman confirmed the company plans to establish a "scientific presence" in the four regions, to identify both early- and late-stage opportunities. "This is consistent with our strategy of actively seeking external scientific innovation to bolster our pipeline with candidates that provide unambiguous promotable advantage," the spokesman said. He declined to comment on potential divestiture plans.
Together, the moves would represent a significant shift for Merck, making it more receptive to external opportunities and less wedded to in-house handling of the entire life cycle of a drug's development, from discovery through clinical trials.
The company has long asked its scientists to stay on top of promising science outside its walls, and has had offices in Boston and Palo Alto, Calif., to further those efforts. Merck became more active doing deals over the past decade, notably its 2009 acquisition of Schering-Plough and the 2011 purchase of Inspire Pharmaceuticals.
Yet the company's laboratories have tended to shun the kinds of full partnerships with outsiders that other pharmaceutical companies now count on heavily for drug candidates and technologies. Merck has also lacked a significant R&D presence in London, while its presence in Shanghai has been primarily commercial operations.
Merck's labs were once the envy of industry, discovering products like the first measles vaccine and the first marketed statin drug to lower cholesterol. Merck researchers prided themselves on carrying drugs from discovery to the last stages of development in-house. But they haven't scored a major success since diabetes drug Januvia and cervical-cancer vaccine Gardasil were approved in 2006.
R&D setbacks have made it harder for Merck to weather patent expirations for top-selling drugs such as the allergy and asthma medication Singulair. Now, they have prompted the company to rethink its inward-looking approach to drug R&D.
In April, Merck brought in a new R&D chief, Roger Perlmutter, who has cut and reorganized personnel and narrowed the scope of projects while shifting resources to more promising opportunities such as an experimental cancer drug tied to the immune system. In October, Merck said it would cut its workforce by 20% over the next two years, including reductions in the R&D unit. Dr. Perlmutter has said the company needs to pursue more external transactions to build up its product line.
The regional hub plan would resemble approaches taken by other leading drug makers. Pfizer Inc. has drastically reduced the size of its longtime R&D center in Groton, Conn., in favor of building up a presence in cities including Boston; Cambridge, U.K.; and La Jolla, Calif. Johnson & Johnson last year unveiled a plan to establish innovation centers in California, Boston, London and China, to focus on identifying early-stage R&D. GlaxoSmithKline PLC recently said it was opening R&D satellite offices in Boston and San Diego to help manage external collaborations and look for new ones.
"The advantage of having these innovation centers is they capture the academic research at a very early stage," said Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development in Boston. As companies like Pfizer and J&J set up innovation hubs in these research hotbeds, their competitors would stand the risk of being left out if they didn't make similar moves, he said.
Dr. Perlmutter has discussed Merck's potential plan for regional innovation hubs in internal meetings with employees, as has Rupert Vessey, who leads early-stage drug discovery at Merck, according to people familiar with the matter.
Merck posted at least two job openings to lead business development and licensing at "innovation hubs" in Boston and San Francisco, according to internal and external online job postings. The jobs are responsible for identifying early-stage research opportunities in their respective regions, and negotiating deals, according to the postings. The Boston job has been filled, according to a Merck posting.
Dr. Perlmutter has also shuffled management at Merck labs. He has hired people he worked with at biotech Amgen Inc., and begun setting up an infrastructure to restock the company's pipeline by doing deals to bring in promising drugs discovered elsewhere.
Dr. Perlmutter has singled out so-called immunotherapies for treating cancer, as well as vaccines, as priorities. Yet he has also said he wants to be less dogmatic about focusing on specific therapeutic areas in the first place, and to be more opportunistic about pursuing the best science, whatever disease it involves. Such an approach requires the means to identify promising areas and seal deals tapping into them.
To facilitate this deal-making, Merck said in August it had hired Iain Dukes as senior vice president of licensing and external science. He was previously vice president of external R&D at Amgen.
Also, Merck has named Roy Baynes as head of global clinical development to replace Barry Gertz, who is retiring. Dr. Baynes had led oncology, inflammation and respiratory therapeutics at Gilead Sciences Inc. since January 2012, and before that held a leadership post at Amgen during Dr. Perlmutter's tenure there.
Write to Peter Loftus at peter.loftus@wsj.com and Jonathan D. Rockoff at jonathan.rockoff@wsj.com
Merck re-org. Whole article is lengthy but I'll paste the whole thing if there's any interest. It's from the WSJ.
By
Peter Loftus And
Jonathan D. Rockoff
connect
Updated Dec. 27, 2013 4:50 p.m. ET
Merck MRK +0.14% & Co. is working on a plan to radically reshape its once-storied research-and-development unit that would create international innovation hubs tapping into drug research outside of its labs.
Merck would create these hubs in or near Boston, the San Francisco Bay area, London and Shanghai, according to people familiar with the matter—regions with a critical mass of academic and commercial R&D. The company would use the bases to scout for promising biotechnology and pharmaceutical research that Merck could license or acquire in deals, according to these people.
Meantime, the company is pruning its own research pipeline. Merck has identified dozens of compounds under study at its labs that it wants to sell off, according to a person familiar with the matter and an internal planning document reviewed by The Wall Street Journal. Among them are experimental glaucoma treatments, some antipsychotics and a male fertility drug, according to the document.
A Merck spokesman confirmed the company plans to establish a "scientific presence" in the four regions, to identify both early- and late-stage opportunities. "This is consistent with our strategy of actively seeking external scientific innovation to bolster our pipeline with candidates that provide unambiguous promotable advantage," the spokesman said. He declined to comment on potential divestiture plans.<snip>
I've found the label and don't see a requirement to have failed other therapies. Could you direct me to the relevant passage?
Not trying to be disputative, BTW. just confused
Iclusig is a kinase inhibitor indicated for the:
• Treatment of adult patients with T315I-positive chronic myeloid
leukemia (chronic phase, accelerated phase, or blast phase) or T315Ipositive Philadelphia chromosome positive acute lymphoblastic
leukemia (Ph+ ALL).
• Treatment of adult patients with chronic phase, accelerated phase, or
blast phase chronic myeloid leukemia or Ph+ ALL for whom no other
tyrosine kinase inhibitor (TKI) therapy is indicated. (1)
These indications are based upon response rate. There are no trials verifying an
improvement in disease-related symptoms or increased survival with Iclusig.
Thank you for your gentle correction. I must have misread the label.
One of the reasons for the current price is the narrowness of the indication.
By that do you mean an M.D. may not begin therapy with Iclusig?
I don't have the label in front of me, but I don't remember that it required the patient have failed prior therapies.
WSJ
BEIJING—China's economy will post growth of 7.6% for all of 2013, a top planning official said, indicating that the world's second-largest economy will exceed Beijing's 7.5% target but that it also lost momentum in the final months of the year.
High-density housing under construction in China, where the government is trying to cool property prices. European Pressphoto Agency
The full-year estimate was revealed by Xu Shaoshi, head of the National Development and Reform Commission, in a report to senior members of the country's top legislative body on Wednesday, according to official media. That compares with a 7.7% growth rate for 2012.
"We cannot deny a downward pressure on economic growth," Mr. Xu told lawmakers, according to the official Xinhua news agency. He cited uncertainties in the global economic recovery and lackluster international demand, Xinhua said.
Some economists said the figure suggested a slowdown near the end of the year following a third-quarter uptick. "If full-year growth is at 7.6%, it means that the economy was slightly worse than market expectations in the fourth quarter," said Nomura economist Wendy Chen.
"We maintain our forecast that the economy peaked in the third quarter, and the moderating trend will extend into the first half of 2014," she said.
China's economy posted year-over-year growth of 7.8% in the third quarter after expanding at 7.7% in the first quarter and 7.5% in the second quarter amid a still sluggish global economy. A "mini-stimulus" of government investment in rail and subway construction coupled with tax and other business incentives helped boost growth in the July-September period.
Senior officials last month concluded a key economic strategy session where they discussed balancing the need to maintain growth while pushing ahead with longer-term goals like dealing with overcapacity and pollution—policies that could slow the economy's momentum even further. No economic target has been announced for 2014, but many economists predict that Beijing will likely set a similar 7.5% goal for the year.
This level of growth indicates Chinese economic growth is "still in an acceptable range," said HSBC economist Ma Xiaoping, referring to the 2013 estimate. "But we need to pay attention to several risk areas such as liquidity conditions in the banking system and a possible slowdown in property investment, especially investments in third- and fourth-tier cities," she said. Third- and fourth-tier cities are still-developing cities compared with the richest cities like Beijing and Shanghai.
Interbank rates—or the rates banks charge when they lend to each other—spiked last week amid a shortage of funds, partly due to year-end factors but also revealing strains in the banking system. A similar cash crunch emerged in June, and both times the central bank stepped in to add liquidity to the market.
Economists suggest that the nation's central bank will likely loosen monetary policy by the second quarter if growth continues to slow next year.
The government has also been trying to cool rising property prices, but it is treading softly as the property market is a major pillar of the economy.
—Yajun Zhang contributed to this article.
Write to William Kazer at william.kazer@wsj.com
Just one good call in 7 years?
EXACTLY a 180 degree distortion of what was written.
Re GregorioAllegri -
I tried to get a reaction to that para out of the ARIA board, but was ignored.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95269785
Too many of the contributors to that board do not like to hear anything that questions their preconceptions, whether it be McMinn or Feuerstein.
Do you have a comment on that para?
The guy may well be a weathervane, but it would be interesting if someone with knowledge of the science could deconstruct the argument of his subpara a) I don't know enough about the science to accept or deny his "working hypothesis".
Good call on this one though scum bag.... How's jail?
Scumbag? Where are the moderators?
According to a comment made by a scientist on the BBC this a.m., the tissue is similar to that of of young mice, but there is no effect in terms of muscle strength.
The scientist was a lady from Oxford, possibly running a competing program. She was British-sniffy about Harvard's publicity capability.
Long, but interesting
WSJ
Kentucky-based Genscape uses cutting edge technology to generate its own sneak peak of U.S. oil production ahead of official government reports. WSJ's Michael Rothfeld reports.
CUSHING, Okla.—A helicopter lifted off recently from an airfield in this remote oil town, scudded low across the flat industrial landscape and trained a heat-sensitive camera at the huge storage tanks below.
Its mission: Gather intelligence for Wall Street.
The grainy, infrared reconnaissance images betrayed how much oil was in each tank. That gave Genscape Inc., the company that conducts the flights, a remarkably accurate preview of a market-moving U.S. government report on oil supplies. Traders, hungry to get a jump on the official data, are willing to pay a hefty price for that intelligence.
Genscape is at the vanguard of a growing industry that employs sophisticated surveillance and data-crunching technology to supply traders with nonpublic information about topics including oil supplies, electric-power production, retail traffic and crop yields.
A satellite image of the parking lot at the Oak Park Mall in Overland Park, Kan., on Black Friday, helped RS Metrics determine how shopper traffic for anchor stores including J.C. Penney compared with previous years. RS Metrics (analysis); Astrium (image)
The techniques, which are perfectly legal, represent the latest advance in the longtime Wall Street practice of searching for every possible trading advantage. But the high cost of much of the new information—Genscape's oil-supply report costs $90,000 a year—means that some forms of trading are becoming even more the province of firms with substantial resources.
Genscape Chief Executive Matthew Burkley says such surveillance brings transparency to markets long dominated by energy giants. Although some energy companies aren't happy about the information gathering, he says, "no one can stop us from doing what we do."
Besides monitoring oil supplies in Cushing, Genscape tracks oil shipments leaving European ports using 800 antenna stations, videotapes railcars of crude oil and follows them to their destinations, calculates the amount of coal burned in the U.S. and western Europe, and even studies crop yields using, among other things, satellite imagery.
Other companies are in the game, too. Remote Sensing Metrics LLC in New York has teamed up with satellite companies, such as Colorado-based DigitalGlobe, to analyze sales at major retail chains such as Lowe's and Target by counting cars in parking lots. DigitalGlobe also uses satellites to assess crops and damage levels at disaster sites.
"With new sources of intelligence available, people find new ways to exploit it for an advantage," says Tony Frazier, a DigitalGlobe vice president.
Two images of fields in São Paulo, Brazil, the bottom one taken in infrared. Darker red areas may indicate how recently crops were watered, and generally reflect their health. RS Metrics (analysis); Astrium (image)
Andrew Lo, a finance professor at Massachusetts Institute of Technology, says advances in technology can make markets more efficient but also can raise questions of fairness. "It can drive less-informed investors out of the market," he says. "Is the information so valuable, and so hard to get, that only a few people can get it? That creates a barrier to entry."
Cushing is the delivery point for U.S. contracts for the benchmark West Texas Intermediate, a light sweet crude commonly refined into gasoline. When there is a buildup of oil in Cushing it indicates that there is an ample supply, and prices tend to drop on the New York Mercantile Exchange. When stocks are declining in Cushing, prices tend to increase.
Every week, the U.S. Energy Information Administration, or EIA, releases a survey that includes Cushing storage levels. Genscape typically releases its report two days before the EIA survey. Between July and late November, Genscape's reports predicted the direction of every change in the EIA report.
Even EIA officials consult Genscape's report before publishing their own survey. When government officials have spotted big discrepancies, they have double-checked with oil companies that submitted data and occasionally discovered errors.
"We just sort of do it as a sanity check," says Douglas MacIntyre, the agency's director of petroleum and biofuel statistics.
During the recent U.S. government shutdown, when federal officials delayed the release of the EIA report, Genscape was a main source of information for investors about the Cushing supply. Genscape released a free version to the general public on the day the government report would have come out. By then, its paying customers had already had it for several days.
Genscape's clients include banks such as Goldman Sachs Group Inc., J.P. Morgan Chase & Co. and Deutsche Bank AG , hedge funds including Citadel LLC and large energy-trading outfits such as Trafigura Beheer BV. Surveillance and analysis of the oil, electricity and natural-gas sectors can run Genscape clients more than $300,000 a year.
Genscape tracks the production of electricity by placing sensors on private property near power plants and transmission lines, which monitor the magnetic and electric fields they create. Genscape uses algorithms to estimate electricity production and transmission.
On Aug. 23, 2011, an earthquake struck in central Virginia, knocking out a nuclear-power plant owned by Dominion Resources Inc. at 1:51 p.m. Eastern time.
One minute later, Genscape sent a "plant alert" to clients indicating that power output had taken a hit at Dominion's North Anna Power Station. A team of Morgan Stanley traders in Purchase, N.Y., saw the alert and realized the incident would trigger demand for electricity from other plants to meet the shortfall, causing prices to increase.
The traders scooped up electricity contracts tied to East Coast power demand that would benefit from the move, said a person familiar with the situation. A Morgan Stanley spokesman declined to comment.
Michael Williams, a trader at Black Oak Energy LLC in Princeton, N.J., uses Genscape to watch new wind farms in the Midwest. On windy days, power from those farms threatens to overload older transmission lines. Mr. Williams says the abundance of power typically leads to price reductions near the wind farms the next day.
“ Genscape tracks electricity production by placing sensors near power plants and transmission lines. ”
On Nov. 13, Mr. Williams learned from Genscape that Fowler Ridge, a 600-megawatt wind farm in Indiana, was operating near capacity. Pioneer Prairie, in Iowa, was at its full 300-megawatt capacity.
He says he sold so-called forward contracts tied to the next day's electricity prices in nearby northern Illinois. He bet that 50 megawatts of power per hour would decrease in price in the coming off-peak period, and he was right. The next day, he settled the contracts for much less than he sold them for—in one case, for nearly one-fifth of the price—profiting by more than $15,000.
Genscape has about 4,000 electromagnetic sensors near transmission lines and power plants around the world. It also uses infrared photos of smoke plumes at power plants to determine if they are producing. Plant operators have no say in the matter because Genscape pays private-property owners to place sensors on their land.
At an office in Boston's Back Bay neighborhood, a Genscape team monitors the power grid and weather in different regions. At around noon one day in August, analysts monitoring parts of the Northeast and Midwest saw a red warning light on their computer screens signaling that part of a coal-fired plant in West Virginia had gone down, taking 1,300 megawatts of electricity with it.
Clients saw what was unfolding on their own screens. The price of a megawatt hour of electricity in the spot market run by the local grid operator was $47 at that point. As the grid operators tried to replace the lost power with electricity from elsewhere, the price rose to $60.
The next day, Genscape analysts adjusted their market models and made new predictions. Later, they fielded questions from traders.
"What's driving the real-time strength today?" one energy trader asked in an instant message to a Genscape analyst. The analyst replied that power plants in certain regions weren't producing enough energy to meet demand, which could indicate volatility—and trading opportunities—for near-term prices.
Power traders Sterling Lapinski and Sean O'Leary founded Genscape in Louisville, Ky., in 2000. Mr. Lapinski says traders without access to the information possessed by power companies operated at "a huge disadvantage."
An infrared image of oil tanks in Cushing, Okla., taken from a helicopter by Genscape, is analyzed by software to determine how full they are. The dark horizontal lines indicate how high the oil goes in each. Genscape
With wireless technology and the help of engineers, he says, the company devised a system to monitor electrical frequencies coming out of plants and create algorithms to turn the "very noisy" data into useful information.
Genscape received venture-capital funding and expanded to monitoring power generation across the U.S. and in Europe. The Department of Homeland Security was a client after Sept. 11, 2001, Genscape says. The agency sought and got a briefing on Genscape's technology, as did the Central Intelligence Agency. The Homeland Security department and CIA declined to comment.
In 2006, Genscape was bought by a U.S. unit of U.K. media group Daily Mail & General Trust PLC for more than $100 million. The founders remain on Genscape's board. Last year, Mr. Lapinski started another company that provides oil-flow information to traders.
In 2009, Genscape began using helicopters to track oil supplies in Cushing, and in 2011, it started reporting on oil-pipeline flows.
This past summer, Genscape alerted clients to a possible shift in the market for West Texas Intermediate crude. Stockpiles in Cushing had steadily declined since July, driving up the price. Many investors had successfully bet that the U.S. crude would narrow the price gap—called the "spread"—with its more expensive European counterpart. In August, U.S. oil briefly surpassed Europe's oil price.
On Aug. 21 at 12:31 p.m., Genscape told clients in an email that nearly 100 railcars of oil from the Bakken had arrived in Stroud, Okla., and were being unloaded at a pipeline that had been dormant for a year. "Increased power consumption at the Stroud pumping station, indicative of moving the oil through the pipeline to Cushing, was observed at approximately 10:30 a.m.," the alert said.
Traders at Deutsche Bank saw the alert as confirmation that Cushing was becoming a more economical delivery point for suppliers again—and if stocks increased there, U.S. oil prices would drop. So they bet against U.S. oil prices, wagering that the price gap with European oil would widen again, said people familiar with the trading.
Genscape's helicopter flyovers in early October also suggested an impending buildup. Using infrared videos of 373 tanks spread over 25 square miles, analysts had been calculating how much oil was in each tank.
After its helicopter flew south over Centurion Pipeline LP's tanks on Oct. 4, Genscape calculated a gain of 123,000 barrels over the previous three days—a 42% increase. Magellan Midstream Partners LP, one of the larger operators in Cushing, showed a 4.4% increase, to more than 5.5 million barrels.
Genscape calculated that although the overall Cushing oil supply had declined since the prior week, it had increased modestly in the second half of the week—the first such increase in months.
Genscape disclosed the information to clients on Oct. 7 at 9 a.m. Over the next half-hour, trading volume spiked and the gap between U.S. and European oil—about $5.25 a barrel—widened by 8%.
Traders also executed bearish bets that day using another futures contract that compares near-term oil prices with prices a year ahead. That contract declined 3% within 25 minutes of the report's release and 7% on the day, reflecting the oil price drops caused by the buildup in Cushing. West Texas Intermediate, which had surpassed $110 a barrel the month before, closed just over $103.
The shift in the second half of the week wasn't reflected in the U.S. government's report two days later, which recorded a 168,000 barrel decline in Cushing.
Many traders remained bullish on U.S. oil prices. It was a bad bet.
On Oct. 14, with no government-oil report coming that week because of the federal shutdown, Genscape told clients that Cushing stocks had a weekly increase of more than 800,000 barrels, another bearish sign for prices.
The firm made those numbers available to the public three days later. The next week, oil prices fell below $100 a barrel for the first time since July.
—Christian Berthelsen
contributed to this article.
Write to Michael Rothfeld at michael.rothfeld@wsj.com and Scott Patterson at scott.patterson@wsj.com
WHAT FDA announcement?
Just a Bernanke rally.
It started well before the Fed announcement.
Sanity lies in never, never opening one of her links.
Please consider yourself liberated of the "obligation"
Merrill
Note: Hess Corp (HES) has been added to the US 1 list today. Anadarko Petroleum (APC) has been removed. Today's closing prices will be the addition/removal prices for the stocks.
Nothing the company says will make a difference. It is what the FDA says will be all that matters (and EMA).
Totally agree. The less the company says, the better.
That includes Berger.
I came out alive.
Just one of the amazing deeds of the Lord.
What relevance does that have to anything I wrote?
No effect on the Hess share price today.
(Release was time stamped "14 hours ago".)